PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
No Data
No Data available this quarter, please select a different quarter.
3.35
Net debt while TRVN maintains net cash position. John Neff would demand higher returns to justify the additional leverage risk.
-958.91
Both companies show negative coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.
3.82
Similar current ratio to TRVN's 3.71. Guy Spier would investigate if industry liquidity norms make sense for both companies.
No Data
No Data available this quarter, please select a different quarter.